RU2312676C2 - Формула кошачьей вакцины - Google Patents

Формула кошачьей вакцины Download PDF

Info

Publication number
RU2312676C2
RU2312676C2 RU2002132832/13A RU2002132832A RU2312676C2 RU 2312676 C2 RU2312676 C2 RU 2312676C2 RU 2002132832/13 A RU2002132832/13 A RU 2002132832/13A RU 2002132832 A RU2002132832 A RU 2002132832A RU 2312676 C2 RU2312676 C2 RU 2312676C2
Authority
RU
Russia
Prior art keywords
plasmid
virus
gene
vaccine
seq
Prior art date
Application number
RU2002132832/13A
Other languages
English (en)
Russian (ru)
Other versions
RU2002132832A (ru
Inventor
Жан-Кристоф ОДОННЕ (FR)
Жан-Кристоф Одонне
Аннабелль БУШАРДОН (FR)
Аннабелль Бушардон
Филипп БОДЮ (FR)
Филипп Бодю
Мишель РИВЬЕР (FR)
Мишель Ривьер
Original Assignee
Мериаль
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мериаль filed Critical Мериаль
Publication of RU2002132832A publication Critical patent/RU2002132832A/ru
Application granted granted Critical
Publication of RU2312676C2 publication Critical patent/RU2312676C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2002132832/13A 1996-07-19 2002-12-05 Формула кошачьей вакцины RU2312676C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9609337 1996-07-19
FR9609337A FR2751223B1 (fr) 1996-07-19 1996-07-19 Formule de vaccin polynucleotidique felin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU99103209/13A Division RU99103209A (ru) 1996-07-19 1997-07-15 Формула кошачей полинуклеотидной вакцины

Publications (2)

Publication Number Publication Date
RU2002132832A RU2002132832A (ru) 2005-01-20
RU2312676C2 true RU2312676C2 (ru) 2007-12-20

Family

ID=9494449

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002132832/13A RU2312676C2 (ru) 1996-07-19 2002-12-05 Формула кошачьей вакцины

Country Status (16)

Country Link
US (2) US6348196B1 (https=)
EP (1) EP0934416B1 (https=)
JP (1) JP2001500112A (https=)
KR (1) KR100687509B1 (https=)
AR (1) AR007861A1 (https=)
AU (1) AU3699297A (https=)
BR (2) BR9715228B1 (https=)
CA (1) CA2261345C (https=)
CZ (2) CZ298613B6 (https=)
DE (1) DE69736185T2 (https=)
FR (1) FR2751223B1 (https=)
NZ (1) NZ333781A (https=)
PL (1) PL191551B1 (https=)
RU (1) RU2312676C2 (https=)
WO (1) WO1998003660A1 (https=)
ZA (1) ZA976286B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2586504C1 (ru) * 2015-04-29 2016-06-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Саратовский государственный аграрный университет имени Н.И. Вавилова" Набор синтетических олигонуклеотидных праймеров и способ его применения для индикации вирусов иммунодефицита и лейкемии кошек в клиническом материале методом мультиплексной полимеразной цепной реакции
RU2749717C2 (ru) * 2015-11-24 2021-06-16 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способ временной трансфекции для продуцирования ретровируса
RU2752498C2 (ru) * 2015-11-24 2021-07-28 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Стабильные клеточные линии для продуцирования ретровирусов
RU2827230C1 (ru) * 2024-03-20 2024-09-23 Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") Ассоциированная вакцина против панлейкопении, калицивироза, вирусного ринотрахеита и бешенства кошек

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2223029A1 (en) 1997-02-12 1998-08-12 Akzo Nobel Nv Canine parvovirus dna vaccines
EP0863151A1 (en) * 1997-02-12 1998-09-09 Akzo Nobel N.V. "Canine parvovirus dna vaccines"
US6770282B1 (en) 1998-10-23 2004-08-03 Heska Corporation Cationic lipid-mediated enhancement of nucleic acid immunization of cats
FR2794648B1 (fr) * 1999-06-10 2003-03-07 Merial Sas Vaccins adn pour animaux de compagnie et de sport
KR100768114B1 (ko) * 1999-06-10 2007-10-17 메리알 애완 동물 및 스포츠용 동물을 위한 ｄｎａ 백신
EP1074625A3 (en) * 1999-06-14 2002-01-02 Pfizer Products Inc. DNA vaccine against feline immunodeficiency virus
DE50010240D1 (de) * 1999-07-08 2005-06-09 Mologen Forschungs Entwicklung Impfstoff gegen infektionen mit lentiviren, wie dem felinen immunschwäche-virus der katze
US6541458B1 (en) 1999-07-16 2003-04-01 Merial Feline calicivirus genes and vaccines in particular recombinant vaccines
FR2796397B1 (fr) * 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines
FR2796396A1 (fr) * 1999-07-16 2001-01-19 Merial Sas Gene de calicivirus felin et vaccin recombine les incorporant
US7078388B2 (en) 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
FR2829498B1 (fr) * 2001-09-11 2003-11-28 Merial Sas Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
AU2003281917A1 (en) * 2002-09-23 2004-04-19 Mologen Ag Vaccine against infections caused by oncoviruses such as the feline leucosis virus of cats
EP1606419A1 (en) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
US20050214316A1 (en) 2003-11-13 2005-09-29 Brown Thomas P Methods of characterizing infectious bursal disease virus
MXPA06009452A (es) 2004-02-19 2007-03-15 Univ Alberta Polimorfismos del promotor de leptin y sus usos.
PT1881845E (pt) 2005-04-25 2010-05-31 Merial Ltd Vacinas de vírus nipah
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
EP3147296A1 (en) 2005-11-14 2017-03-29 Merial, Inc. Gene therapy for renal failure
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
UA100692C2 (ru) 2007-05-02 2013-01-25 Мериал Лимитед Днк-плазмиды, имеющие повышенную экспрессию и стабильность
WO2010115133A2 (en) 2009-04-03 2010-10-07 Merial Limited Newcastle disease virus vectored avian vaccines
WO2012030720A1 (en) 2010-08-31 2012-03-08 Merial Limited Newcastle disease virus vectored herpesvirus vaccines
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
US20140296248A1 (en) 2011-04-04 2014-10-02 Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
EP2694678A2 (en) 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
HK1200329A1 (en) 2011-04-25 2015-08-07 先进生物学实验室股份有限公司 Truncated hiv envelope proteins (env), methods and compositions related thereto
CA2837375C (en) 2011-06-01 2019-07-16 Merial Limited Needle-free administration of prrsv vaccines
SI2741740T1 (sl) 2011-08-12 2017-08-31 Merial, Inc. Vakuumsko konzerviranje bioloških proizvodov, zlasti cepiv
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
WO2014164697A1 (en) 2013-03-12 2014-10-09 Merial Limited Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof
CA2966191A1 (en) 2014-11-03 2016-05-12 Merial, Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
DK3313864T3 (da) 2015-06-23 2021-11-01 Boehringer Ingelheim Animal Health Usa Inc Rekombinante virusvektorer indeholdende prrsv minor protein og fremgangsmåder til fremstilling og anvendelse deraf
CN112921122A (zh) * 2021-03-26 2021-06-08 广西大学 猫常见病毒多重pcr快速检测试剂盒及其引物组
CN112921123B (zh) * 2021-04-06 2022-11-04 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 快速检测猫杯状病毒的方法及检测用引物和试剂盒
CN115894716B (zh) * 2022-11-23 2024-02-09 华中农业大学 一种重组融合蛋白纳米颗粒及其制备方法
CN116218889A (zh) * 2022-12-13 2023-06-06 浙江大学 一种表达猫细小病毒VP2蛋白的mRNA疫苗及其制备方法
CN116121282B (zh) * 2023-01-10 2023-09-22 浙江大学 一种表达猫疱疹病毒蛋白的mRNA疫苗及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
CA2020740A1 (en) * 1989-07-12 1991-01-13 Harry Vennema Antigenically active proteins/peptides, and feline infectious peritonitis virus (fipv)-vaccines
DE69017687T2 (de) * 1989-07-21 1995-10-19 Upjohn Co Felincalicivirus-capsid-protein und nukleotidsequenz.
US5665362A (en) * 1990-09-25 1997-09-09 Cantab Pharmaceuticals Research Limited Viral vaccines
WO1993015762A1 (en) * 1992-02-18 1993-08-19 Parhelion Corporation Feline infectious peritonitis vaccine and method of preparation
CA2142325A1 (en) * 1992-09-21 1994-03-31 William T. L. Lee Recombinant retroviral vector against felv and/or fiv
GB2282601B (en) * 1993-09-16 1998-04-15 Solvay Antigenically-active proteins/polypeptides and coronavirus vaccines containing the same
US6348449B1 (en) * 1993-09-21 2002-02-19 The Trustees Of The University Of Pennsylvania Methods of inducing mucosal immunity
TW377373B (en) * 1993-09-22 1999-12-21 Wyeth Corp Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease
ATE475668T1 (de) * 1994-01-27 2010-08-15 Univ Massachusetts Medical Immunisierung durch impfung von dns transkriptionseinheit
US5529780A (en) * 1994-03-30 1996-06-25 Virogenetics Corporation Nucleotide and amino acid sequences of canine herpesvirus gB and gC
ES2267101T3 (es) * 1994-04-29 2007-03-01 PHARMACIA & UPJOHN COMPANY LLC Vacuna contra virus de inmunodeficiencia felina.
FR2724385B1 (fr) * 1994-08-29 1996-12-13 Rhone Merieux Vaccin de la peritonite infectieuse feline.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FLYNN J.N. et al. Involvement of gag- and env-specific cytotoxic Т lymphocytes in protective immunity to feline immunodeficiency virus. AIDS Res. Hum. Retroviruses. 1995 Sep; 11(9): 1107-13. *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2586504C1 (ru) * 2015-04-29 2016-06-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Саратовский государственный аграрный университет имени Н.И. Вавилова" Набор синтетических олигонуклеотидных праймеров и способ его применения для индикации вирусов иммунодефицита и лейкемии кошек в клиническом материале методом мультиплексной полимеразной цепной реакции
RU2749717C2 (ru) * 2015-11-24 2021-06-16 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способ временной трансфекции для продуцирования ретровируса
RU2752498C2 (ru) * 2015-11-24 2021-07-28 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Стабильные клеточные линии для продуцирования ретровирусов
RU2827230C1 (ru) * 2024-03-20 2024-09-23 Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") Ассоциированная вакцина против панлейкопении, калицивироза, вирусного ринотрахеита и бешенства кошек

Also Published As

Publication number Publication date
CZ304126B6 (cs) 2013-11-06
EP0934416B1 (fr) 2006-06-21
DE69736185T2 (de) 2007-04-19
BR9710497B1 (pt) 2011-04-05
FR2751223B1 (fr) 1998-12-04
PL331247A1 (en) 1999-07-05
KR100687509B1 (ko) 2007-10-12
AR007861A1 (es) 1999-11-24
DE69736185D1 (de) 2006-08-03
CA2261345A1 (en) 1998-01-29
KR20000065257A (ko) 2000-11-06
BR9710497A (pt) 1999-08-17
AU3699297A (en) 1998-02-10
CA2261345C (en) 2010-09-14
JP2001500112A (ja) 2001-01-09
BR9715228B1 (pt) 2011-10-04
RU2002132832A (ru) 2005-01-20
US7534559B2 (en) 2009-05-19
WO1998003660A1 (fr) 1998-01-29
ZA976286B (en) 1999-01-19
PL191551B1 (pl) 2006-06-30
EP0934416A1 (fr) 1999-08-11
FR2751223A1 (fr) 1998-01-23
US6348196B1 (en) 2002-02-19
US20030017172A1 (en) 2003-01-23
CZ15999A3 (cs) 1999-06-16
NZ333781A (en) 2000-09-29
CZ298613B6 (cs) 2007-11-21

Similar Documents

Publication Publication Date Title
RU2312676C2 (ru) Формула кошачьей вакцины
RU2319504C2 (ru) Вакцина собак против бешенства (варианты), способ вакцинации (варианты), набор для вакцинации (варианты)
CA2660355C (en) Polynucleotide vaccine formulation against pathologies of the horse
RU2305560C2 (ru) Формула вакцины против респираторных патологий крупного рогатого скота
RU2305559C2 (ru) Вакцина свиней против респираторных патологий и патологий репродукции свиней
AU735184B2 (en) Avian polynucleotide vaccine formula
US7294338B2 (en) Polynucleotide vaccine formula against canine pathologies, in particular respiratory and digestive pathologies
AU773266B2 (en) Feline polynucleotide vaccine formula
AU2004205140B2 (en) Feline polynucleotide vaccine formula
AU2004210602B2 (en) Avian polynucleotide vaccine formula
AU2008203549A1 (en) Feline polynucleotide vaccine formula
NZ506427A (en) A canidae vaccine comprising the rabies G gene under the control of the CMV-IE promoter
HK1083763A (zh) 针对马科动物病变的多核苷酸疫苗配方
AU2007202367A1 (en) Avian polynucleotide vaccine formula
AU5427401A (en) Polynucleotide vaccine formula for treating horse diseases
AU4614101A (en) Avian polynucleotide vaccine formula